Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

Bibliography

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R: Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Supp. Cancer Therapy2,181–187 (2005).
  MedlineGoogle Scholar
• 2  Cohen L, de Moor CA, Eisenberg P et al.: Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support. Care Cancer15(5),497–503 (2005).
  Google Scholar
• 3  Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch JR: Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer97,2880–2886 (2003).▪ Excellent review of chemotherapy-induced nausea and vomiting (CINV).
  Medline CASGoogle Scholar
• 4  Grunberg SM, Deuson R, Mavros P et al.: Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics: perception versus reality. Cancer100,2261–2268 (2004).▪ Good review of patients’ perspective of CINV.
  MedlineGoogle Scholar
• 5  Grunberg SM, Osoba D, Hesketh PJ et al.: Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support. Care Cancer13,80–84 (2005).
  MedlineGoogle Scholar
• 6  Navari RM, Province PS: Emerging drugs for chemotherapy-induced emesis. Expert Opin. Emerging Drugs11,137–151 (2006).
  Medline CASGoogle Scholar
• 7  Navari RM: Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs69(5),515–533 (2009).
  Medline CASGoogle Scholar
• 8  Roila F, Warr D, Clark-Snow R et al.: Delayed emesis: moderately emetogenic chemotherapy. Support. Care Cancer13(2),104–108 (2005).
  MedlineGoogle Scholar
• 9  Geling O, Eichler H: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol.23,1289–1294 (2005).
  Medline CASGoogle Scholar
• 10  Hickok JT, Roscoe JA, Morrow GR et al.: 5-HT₃ receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol.6,765–772 (2005).
  Medline CASGoogle Scholar
• 11  Hesketh PJ: New treatment options for chemotherapy-induced nausea and vomiting. Support. Care Cancer12,550–554 (2004).
  MedlineGoogle Scholar
• 12  Navari RM: Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J. Support. Oncol.1,89–103 (2003).
  Medline CASGoogle Scholar
• 13  Kris MG, Hesketh PJ, Somerfield MR et al.; American Society of Clinical Oncology: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol.24(18),2932–2947 (2006).
  Medline CASGoogle Scholar
• 14  Simpson K, Spencer CM, McClellan KJ: Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs59,1297–1315 (2000).
  Medline CASGoogle Scholar
• 15  Kimura E, Niimi E, Watanabe A et al.: Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho.23,477–481 (1996).
  Medline CASGoogle Scholar
• 16  Taguchi T, Tsukamoto F, Watanabe T et al.: Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho.26,1163–1170 (1999).
  Medline CASGoogle Scholar
• 17  Navari RM, Koeller JM: Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann. Pharmacother.37,1276–1286 (2003).▪ Excellent review of the first-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonists.
  Medline CASGoogle Scholar
• 18  WHO Drug Information. 20. No. 3 (2006).
  Google Scholar
• 19  Eisenberg P, Figueroa-Vadillo J, Zamora R et al.: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT₃ receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer98,2473–2482 (2003).▪ Data used for the US FDA approval of palonosetron.
  Medline CASGoogle Scholar
• 20  Gralla R, Lichinitser M, Van Der Vegt S et al.: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol.14,1570–1577 (2003).▪▪ Data used for the FDA approval of palonosetron.
  Medline CASGoogle Scholar
• 21  Eisenberg P, MacKintosh FR, Ritch P et al.: Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol.15,330–337 (2004).
  Medline CASGoogle Scholar
• 22  Aapro MS, Grunberg SM, Manikhas GM et al.: A Phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol.17,1441–1449 (2006).▪▪ Data used for the FDA approval of palonosetron.
  Medline CASGoogle Scholar
• 23  Saito M, Aogi K, Sekine I et al.: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative Phase III trial. Lancet Oncol.10,115–124 (2009).
  Medline CASGoogle Scholar
• 24  DeJonghe BC, Horn CC: Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). Am J. Physiol. Regul. Integr. Comp. Physiol.294(4),R902–R911 (2009).
  Google Scholar
• 25  Aloxi^® (palonosetron HCl) injection, prescribing information. Eisai, Inc., Woodcliffe Lake, NJ, USA (2008).
  Google Scholar
• 26  Cantoreggi S, Parisi S, Van Laar E et al.: Palonosetron, a new 5-HT₃ antagonist does not alter anti-tumor efficacy of various chemotherapeutics in tumor bearing mice. Clin. Cancer Res.9,6254S (2003) (Abstract).
  Google Scholar
• 27  Decker GM, DeMeyer ES, Kisko DL: Measuring the maintenance of daily life activities using the Fuctional Living Index–Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J. Support. Oncol.4,35–41 (2006).
  MedlineGoogle Scholar
• 28  Cartmell AD, Ferguson S, Yanagihara R et al.: Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT₃ receptor antagonist. Proc. Am. Soc. Clin. Oncol.756 (2003) (Abstract 3041).
  Google Scholar
• 29  Yu Z, Liu W, Wang L et al.: The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a Phase II, multicenter, randomized, comparative clinical trial. Support. Care Cancer17(1),99–102 (2009).
  MedlineGoogle Scholar
• 30  Rojas C, Stathis M, Thomas AG et al.: Palonosetron exhibits unique molecular interactions with the 5HT₃ receptor. Anesth. Analg.107,353–355 (2008).
  MedlineGoogle Scholar
• 31  Rojas C, Thomas AG, Alt J et al.: Palonosetron triggers 5-HT₃ receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol.626,193–199 (2010).
  Medline CASGoogle Scholar
• 32  Grote T, Hajdenberg J, Cartmell AD et al.: Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy induced nausea and vomiting after emetogenic chemotherapy. J. Support. Oncol.4,403–408 (2006).
  Medline CASGoogle Scholar
• 33  Shah A, DeGroot T, Apseloff G: Pharmacokinetic evaluation and safety profile of a 15 min versus 30 second infusion of palonosetron in healthy subjects. J. Clin. Pharmacol.46,1139–1145 (2006).
  Medline CASGoogle Scholar
• 34  Stoltz R, Cyong J, Shah A, Parisi S: Pharmacokinetic and safety evaluation of palonosetron, a 5HT₃ receptor antagonist, in U.S. and Japanese healthy subjects. J. Clin. Pharmacol.44,520–531 (2004).
  Medline CASGoogle Scholar
• 35  Aapro MS, Macciocchi A, Gridelli C: Palonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patients. J. Support. Oncol.3,369–374 (2005).
  Medline CASGoogle Scholar
• 36  Hajdenberg J, Grote T, Yee L et al.: Infusion of palonosetron plus dexamethasone is effective and safe for the prevention of chemotherapy-induced nausea and vomiting. J. Support. Oncol.4,467–471 (2006).
  Medline CASGoogle Scholar
• 37  Navari RM, Einhorn LH, Loehrer PJ et al.: A Phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting. Support. Care Cancer15,1285–1291 (2007).▪▪ Describes the use of olanzapine as an antiemetic.
  MedlineGoogle Scholar
• 38  Navari RM, Einhorn LH, Loehrer PJ et al.: A Phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support. Care Cancer13,529–534 (2005).
  MedlineGoogle Scholar
• 39  Cleeland CS, Mendoza TR, Wang, XS et al.: Assessing symptom distressing cancer patients: the M.D. Anderson Symptom Inventory. Cancer89,1634–1646 (2000).
  Medline CASGoogle Scholar
• 40  Rzepecki P, Plelichowski W, Oborska S et al.: Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before hematopoietic stem cell transplantation – single center experience. Transplantation Proc.41(8),3247–3249 (2009).
  Medline CASGoogle Scholar
• 41  Einhorn LH, Brames MJ, Dreicer R et al.: Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support. Care Cancer15,1293–1300 (2007).
  MedlineGoogle Scholar
• 42  Navari RM: Prevention of emesis from multiple-day chemotherapy regimens. J. Natl Compr. Canc. Netw.5,51–59 (2007).
  Medline CASGoogle Scholar
• 43  Musso M, Scalone R, Bonanno V et al.: Palonosetron and dexamethasone for the Prevention of acute and delayed nausea and vomiting in patients receiving multi-day chemotherapy. Support. Care Cancer17,205–209 (2009).
  MedlineGoogle Scholar
• 44  Bissoli F, McGiuggan M, Bertazzoli M: Post-marketing experience of palonosetron confirms a favorable benefit/risk profile. Support. Care Cancer13(413),A04 (2005).
  Google Scholar
• 45  Hajdenberg J: Safety profile of palonosetron, a pharmacologically distinct 5-HT₃ receptor antagonist recently approved for acute and delayed chemotherapy induced nausea. Blood102,510B (2003) (Abstract 5770).
  Google Scholar
• 46  Morganroth J, Parisi S, Moresino C et al.: High dose palonosetron does not alter parameters including QT_C interval in healthy subjects: results of a dose–response, double blind, randomized, parallel E14 study of palonosetron versus moxifloxacin or placebo. Eur. J. Cancer Supple.5(4),158 (2007) (Abstract 1156).
  Google Scholar
• 47  Raftopoulas H, Bria E, Gralla R et al.: Is there a preferred dose of palonosetron? Results of an abstracted data meta-analysis of all eight randomized double-blind studies and the impact on guideline considerations. J. Clin. Oncol.27,15S (2009) (Abstract 9636).
  Google Scholar
• 101  ASCO patient guide: preventing nausea and vomiting caused by cancer treatment (2006) www.plwc.org (Accessed August 2009)
  Google Scholar
• 102  The NCCN clinical practice guidelines in oncology (2009) www.nccn.org (Accessed August 2009)
  Google Scholar
• 103  Multinational Association of Supportive Care in Cancer antiemetic guidelines (2009) www.mascc.org (Accessed August 2009)
  Google Scholar